Thinning of the bone

Reduce thinning of the bone with Preotact®

Osteoporosis is a bone disease that results in thinning of the bone and loss in bone strength. A thinning of the bone results in lower bone density or bone mass, resulting in a greater risk of bone fracture. Osteoporosis and thinning of bone is most common in women after menopause due to estrogen deficiency - this is also known as postmenopausal osteoporosis. 

Preotact® is approved for the treatment of osteoporosis in post-menopausal women at high risk of fractures. Preotact^® stimulates the growth of structurally normal bone and improves bone density and quality, hereby reducing thinning of the bone and the risk of bone fracture.

Log in to learn more about thinning of the bone

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.